University of Wisconsin, Madison
Welcome,         Profile    Billing    Logout  
 83 Trials 
55 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LoConte, Noelle
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
Teng, Joyce
VAPAUS, NCT05180708: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

Completed
3
87
Europe, US
QTORIN 3.9% rapamycin anhydrous gel, Vehicle
Palvella Therapeutics, Inc.
Pachyonychia Congenita
06/23
06/23
SELVA, NCT06239480: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Recruiting
3
40
US
QTORIN 3.9% Rapamycin Anhydrous Gel
Palvella Therapeutics, Inc., FDA Office of Orphan Products Development
Microcystic Lymphatic Malformation
01/26
07/26
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Recruiting
2/3
80
Europe, US, RoW
AC-203, Vehicle
TWi Biotechnology, Inc.
Generalized Epidermolysis Bullosa Simplex
08/25
03/26
EPIK-L1, NCT05948943: Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Recruiting
2/3
230
Europe, US, RoW
Alpelisib, BYL719, Placebo
Novartis Pharmaceuticals
Lymphatic Malformations
10/27
05/30
PALV-04, NCT04893486: CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Completed
2
73
Europe, US
PTX-022, Vehicle comparator
Palvella Therapeutics, Inc.
BCCs in Gorlin Syndrome Patients
03/23
03/23
TAMES, NCT05062070: Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex

Completed
1/2
6
US
TolaSure Topical Gel, Active Ingredient BM-3103, Vehicle Topical Gel, TolaSure Vehicle Gel
BioMendics, LLC
Epidermolysis Bullosa Simplex
06/23
06/23
NCT02057614: Topical Sirolimus for Plantar Keratoderma in Adults With Pachyonychia Congenita (PC)

Recruiting
1
15
US
Topical Sirolimus
Stanford University, TransDerm, Inc., Pachyonychia Congenita Project
Pachyonychia Congenita, Plantar Keratoderma
12/14
 
Campbell, Toby
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
Benca, Ruth M
NCT05771844: Home Sleep Therapy for Older Adults With MCI

Recruiting
N/A
82
US
Transcranial Electrical Stimulation, SleepWISP (Wireless Interface Sensor Pod)
Brain Electrophysiology Laboratory Company, National Institute on Aging (NIA), Wake Forest University
Mild Cognitive Impairment, Sleep, Transcranial Electrical Stimulation, Machine Learning, Memory
06/26
06/26
Cho, Steve
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
02/25
02/25
VENICE, NCT05280366: STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

Active, not recruiting
N/A
150
US, RoW
Streamline Surgical System, iStent Inject W
New World Medical, Inc.
Open Angle Glaucoma
06/26
06/26
Reeder, Scott B
NCT03674528: Technical Validation of MR Biomarkers of Obesity-Associated NAFLD

Completed
N/A
152
US
Magnetic Resonance Elastography (MRE), MRI, Liver biopsy, Intraoperative Biopsy
University of Wisconsin, Madison, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), GE Healthcare, Pfizer, Siemens Medical Solutions, National Center for Advancing Translational Sciences (NCATS)
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
06/24
06/24
Yang, Paul
NCT04850118: A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Recruiting
2/3
75
Europe, US, RoW
rAAV2tYF-GRK1-hRPGRco, AGTC-501, Control, Untreated Control Group
Beacon Therapeutics
X-Linked Retinitis Pigmentosa
08/25
10/29
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Barroilhet, Lisa
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
Huckfeldt, Rachel M
NCT04671433 / 2020-002873-88: Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Completed
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR, botaretigene sparoparvovec
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/24
09/24
MGT-RPGR-022, NCT04794101 / 2020-002255-37: Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Active, not recruiting
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR Intermediate Dose, botaretigene sparoparvovec, Genetic: AAV5-hRKp.RPGR Low Dose
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/29
12/29
NCT04312672 / 2018-000425-31: Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Active, not recruiting
1/2
42
Europe, US
AAV5-hRKp.RPGR
Janssen Research & Development, LLC, MeiraGTx UK II Ltd, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
11/26
11/26
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Connect, Cancer
ROCKnrol-1, NCT06143891: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Recruiting
3
260
Europe, Canada, US, RoW
Belumosudil, SAR445761/ KD025, REZUROCK, Placebo, Prednisone, Prednisolone
Sanofi
Chronic Graft Versus Host Disease
09/28
09/28
SMILE, NCT04738292: Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The Study)

Terminated
2
11
US
Onapristone, Fulvestrant, Fulvestrant Injection
University of Wisconsin, Madison, Context Therapeutics Inc.
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
04/23
05/23
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
NCI-2018-02551, NCT03725761: Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Active, not recruiting
2
31
US
Sacituzumab Govitecan, IMMU-132
University of Wisconsin, Madison, National Cancer Institute (NCI), Gilead Sciences
Prostate Cancer
04/24
04/25
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
BTCRC LUN20-462, NCT04919382: Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Recruiting
2
56
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
Dwight Owen, Genentech, Inc.
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/25
12/26
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT05846646: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC

Terminated
2
6
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligometastatic Disease
09/24
09/24
NCT05846659: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

Terminated
2
16
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligoprogressive
11/24
11/24
NCT01743950: A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

Terminated
2
49
US
Bevacizumab, PRDR, re-irradiation
University of Wisconsin, Madison, Genentech, Inc., National Cancer Institute (NCI)
Glioma
12/24
12/24
NCI-2019-07966, NCT04150640: Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Recruiting
2
52
US
Nal-IRI, liposomal irinotecan, Oxaliplatin, 5-FU, Fluorouracil, Trastuzumab, Pembrolizumab, Nivolumab
University of Wisconsin, Madison, Ipsen
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
12/25
12/26
BTCRC-BRE18-337, NCT03911973: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Active, not recruiting
1/2
37
US
Gedatolisib, Talazoparib
Kari Wisinski, Pfizer, Celcuity Inc
TNBC - Triple-Negative Breast Cancer
07/24
07/24
NCT03090165: Ribociclib and Bicalutamide in AR+ TNBC

Recruiting
1/2
37
US
ribociclib, LEE011, Bicalutamide
Kari Wisinski, Novartis, Big Ten Cancer Research Consortium, University of Wisconsin, Madison
Triple Negative Breast Cancer
09/25
09/25
NCT05230810: Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Recruiting
1/2
40
US
Alpelisib, Piqray, Tucatinib, Tukysa, Fulvestrant, Faslodex,
Criterium, Inc., Novartis, Seagen Inc.
HER2-positive Metastatic Breast Cancer
08/24
06/25
NCT04989946: Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Recruiting
1/2
60
US
Degarelix, pTVG-AR, Nivolumab, Opdivo, Cemiplimab, Libtavo, Fianlimab, REGN3767, FLT PET/CT, 3'-Deoxy-3'-[18F]Fluorothymidine (FLT) positron emission tomography (PET) /computed tomography (CT)
University of Wisconsin, Madison, Madison Vaccines, Inc, United States Department of Defense, Regeneron Pharmaceuticals, Bristol-Myers Squibb, National Cancer Institute (NCI)
Prostate Cancer
12/26
12/28
NCT05655312: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Recruiting
1/2
264
US
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Perspective Therapeutics
Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
12/27
12/29
CUE-102-01, NCT05360680: A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Active, not recruiting
1
52
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
12/24
12/26
NCT05568680: SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Recruiting
1
42
US
SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Verismo Therapeutics
Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
12/27
12/27
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Active, not recruiting
1
54
Europe, US, RoW
KIN-3248
Kinnate Biopharma
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
06/26
09/26
ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting
1
120
Japan, US, RoW
EO-3021
Elevation Oncology
Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
09/28
12/28
NCT05094102: Intraoperative Evaluation of Axillary Lymphatics

Completed
N/A
9
US
OnLume Imaging System, Indocyanine green, ICG
University of Wisconsin, Madison, National Institutes of Health (NIH), OnLume Inc., National Cancer Institute (NCI)
Lymphedema, Surgery, Breast Cancer
04/23
04/23
NCT06701201: A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

Not yet recruiting
N/A
60
US
SynKIR-110, SynKIR-310
Verismo Therapeutics
Cancer
02/42
02/42
Yakey, Janice
#HOPE4LIVER US, NCT04572633: The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy

Active, not recruiting
N/A
47
US
HistoSonics System, Histotripsy
HistoSonics, Inc.
Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
01/23
07/26
Schultz, Meredith
REVEAL, NCT05606614: Safety and Efficacy of TSHA-102 in Adolescent and Adult Females with Rett Syndrome ( Adult Study)

Recruiting
1/2
18
Canada, US
TSHA-102
Taysha Gene Therapies, Inc.
Rett Syndrome
01/25
01/32
NCT06152237: Safety and Efficacy of TSHA-102 in Pediatric Females with Rett Syndrome (REVEAL Pediatric Study)

Recruiting
1/2
20
Europe, Canada, US
TSHA-102
Taysha Gene Therapies, Inc.
Rett Syndrome
11/28
11/31
Murphy, Megan
NCT03819387: A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Completed
1
49
US
NBF-006
Nitto BioPharma, Inc.
Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
11/23
03/24
Maldonado, Ramiro S
Guardian, NCT05956626: Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease

Recruiting
1/2
42
US
OCU410ST
Ocugen
Stargardt Disease
10/25
10/25
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Vakil, Manini
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Hugar, Sarah Isabel
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Thomas, Sierra
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Manager, MICT Global Research
NCT06769594: Silicon Photon Counting CT

Not yet recruiting
N/A
100
US
Investigational Photon-Counting CT Scan
GE Healthcare, University of Wisconsin, Madison
Computed Tomography
12/25
12/25
Smith, Kristin
NCT06769594: Silicon Photon Counting CT

Not yet recruiting
N/A
100
US
Investigational Photon-Counting CT Scan
GE Healthcare, University of Wisconsin, Madison
Computed Tomography
12/25
12/25

Download Options